Apoptosis signal-regulating kinase inhibitor

Patent metadata

Field	Value
Publication number	US-9750730-B2
Application number	US-201615140204-A
Country	US
Kind code	B2
Filing date	Apr 27, 2016
Priority date	Jan 27, 2012
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The present invention relates to a compound of formula (I):

The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.

First claim

What is claimed is:

1. A method of treating liver fibrosis comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the liver fibrosis is selected from the group consisting of, chronic liver fibrosis and acute liver fibrosis.

3. The method of claim 1 , wherein the pharmaceutically acceptable salt is the hydrochloride salt.

4. The method of claim 1 , wherein the therapeutic amount ranges from 1 mg to 250 mg.

5. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered orally.

6. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a single or multiple doses.

7. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with other therapeutic agents.

8. The method of claim 7 , wherein the one or more therapeutic agents is selected from the group consisting of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive agents, antibiotic agents, analgesic agents, antidepressant agents, or antianxiety agents.

9. The method of claim 7 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered simultaneously.

10. The method of claim 7 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered one after the other within intervals.

Assignees

• Gilead Sciences Inc

Inventors

• Notte Gregory

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title